Tenvie Therapeutics
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $200.0Mattributed |
|---|---|
| Latest round | series-a, $200.0M, 2025-01-08attributed |
| Founded | 2023 |
| Headquarters | South San Francisco |
| Industry | bio |
| Stage | series-a |
| Website | tenvietx.com |
Tenvie Therapeutics develops brain-penetrant small-molecule drugs targeting inflammation, metabolic dysfunction, and lysosomal pathways, led by an NLRP3 inhibitor (TNV262) and an allosteric SARM1 inhibitor. It treats neurological, cardiometabolic, and ophthalmic disease. Tenvie inherits a pipeline acquired from Denali Therapeutics.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-01-08 | series-a | $200.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $200.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $200.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | tenvietx.com, read 2026-05-07 |
| Description | self-reported | tenvietx.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.